Literature DB >> 26652247

3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.

Fangrui Wu1, Chao Zhou1, Yuan Yao1, Liping Wei1, Zizhen Feng1, Lisheng Deng1, Yongcheng Song1,2.   

Abstract

Methylation of histone lysine residues plays important roles in gene expression regulation as well as cancer initiation. Lysine specific demethylase 1 (LSD1) is responsible for maintaining balanced methylation levels at histone H3 lysine 4 (H3K4). LSD1 is a drug target for certain cancers, due to important functions of methylated H3K4 or LSD1 overexpression. We report the design, synthesis, and structure-activity relationships of 3-(piperidin-4-ylmethoxy)pyridine containing compounds as potent LSD1 inhibitors with Ki values as low as 29 nM. These compounds exhibited high selectivity (>160×) against related monoamine oxidase A and B. Enzyme kinetics and docking studies suggested they are competitive inhibitors against a dimethylated H3K4 substrate and provided a possible binding mode. The potent LSD1 inhibitors can increase cellular H3K4 methylation and strongly inhibit proliferation of several leukemia and solid tumor cells with EC50 values as low as 280 nM, while they had negligible effects on normal cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26652247      PMCID: PMC4878443          DOI: 10.1021/acs.jmedchem.5b01361

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  59 in total

Review 1.  Epigenetic regulation in psychiatric disorders.

Authors:  Nadia Tsankova; William Renthal; Arvind Kumar; Eric J Nestler
Journal:  Nat Rev Neurosci       Date:  2007-05       Impact factor: 34.870

2.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

Review 3.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

4.  Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.

Authors:  K Mrózek; K Heinonen; D Lawrence; A J Carroll; P R Koduru; K W Rao; M P Strout; R E Hutchison; J O Moore; R J Mayer; C A Schiffer; C D Bloomfield
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

5.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.

Authors:  Philip Kahl; Lucia Gullotti; Lukas Carl Heukamp; Susanne Wolf; Nicolaus Friedrichs; Roland Vorreuther; Gerold Solleder; Patrick J Bastian; Jörg Ellinger; Eric Metzger; Roland Schüle; Reinhard Buettner
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

Review 6.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

7.  Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.

Authors:  Wenyu Yu; Emma J Chory; Amy K Wernimont; Wolfram Tempel; Alex Scopton; Alexander Federation; Jason J Marineau; Jun Qi; Dalia Barsyte-Lovejoy; Joanna Yi; Richard Marcellus; Roxana E Iacob; John R Engen; Carly Griffin; Ahmed Aman; Erno Wienholds; Fengling Li; Javier Pineda; Guillermina Estiu; Tatiana Shatseva; Taraneh Hajian; Rima Al-Awar; John E Dick; Masoud Vedadi; Peter J Brown; Cheryl H Arrowsmith; James E Bradner; Matthieu Schapira
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

8.  High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.

Authors:  Venkataswamy Sorna; Emily R Theisen; Bret Stephens; Steven L Warner; David J Bearss; Hariprasad Vankayalapati; Sunil Sharma
Journal:  J Med Chem       Date:  2013-11-23       Impact factor: 7.446

9.  The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation.

Authors:  Jing Wang; Sarah Hevi; Julia K Kurash; Hong Lei; Frédérique Gay; Jeffrey Bajko; Hui Su; Weitao Sun; Hua Chang; Guoliang Xu; François Gaudet; En Li; Taiping Chen
Journal:  Nat Genet       Date:  2008-12-21       Impact factor: 38.330

10.  Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.

Authors:  Joanne M Hilden; Patricia A Dinndorf; Sharon O Meerbaum; Harland Sather; Doojduen Villaluna; Nyla A Heerema; Ron McGlennen; Franklin O Smith; William G Woods; Wanda L Salzer; Helen S Johnstone; Zoann Dreyer; Gregory H Reaman
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

View more
  20 in total

Review 1.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

2.  Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.

Authors:  Fangrui Wu; Yuanda Hua; Salma Kaochar; Shenyou Nie; Yi-Lun Lin; Yuan Yao; Jingyu Wu; Xiaowei Wu; Xiaoyong Fu; Rachel Schiff; Christel M Davis; Matthew Robertson; Erik A Ehli; Cristian Coarfa; Nicholas Mitsiades; Yongcheng Song
Journal:  J Med Chem       Date:  2020-04-21       Impact factor: 7.446

3.  Discovery, X-ray Crystallography and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease.

Authors:  Yuan Yao; Tong Huo; Yi-Lun Lin; Shenyou Nie; Fangrui Wu; Yuanda Hua; Jingyu Wu; Alexander R Kneubehl; Megan B Vogt; Rebecca Rico-Hesse; Yongcheng Song
Journal:  J Am Chem Soc       Date:  2019-04-23       Impact factor: 15.419

Review 4.  Histone lysine specific demethylase 1 inhibitors.

Authors:  Samir Mehndiratta; Jing-Ping Liou
Journal:  RSC Med Chem       Date:  2020-07-31

5.  Discovery of [1,2,3]Triazolo[4,5-d]pyrimidine Derivatives as Novel LSD1 Inhibitors.

Authors:  Zhong-Hua Li; Xue-Qi Liu; Peng-Fei Geng; Feng-Zhi Suo; Jin-Lian Ma; Bin Yu; Tao-Qian Zhao; Zhao-Qing Zhou; Chen-Xi Huang; Yi-Chao Zheng; Hong-Min Liu
Journal:  ACS Med Chem Lett       Date:  2017-03-06       Impact factor: 4.345

6.  Synthesis, Structure-Activity Relationships, and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease.

Authors:  Shenyou Nie; Yuan Yao; Fangrui Wu; Xiaowei Wu; Jidong Zhao; Yuanda Hua; Jingyu Wu; Tong Huo; Yi-Lun Lin; Alexander R Kneubehl; Megan B Vogt; Josephine Ferreon; Rebecca Rico-Hesse; Yongcheng Song
Journal:  J Med Chem       Date:  2021-02-17       Impact factor: 7.446

Review 7.  Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives.

Authors:  Yongcheng Song; Fangrui Wu; Jingyu Wu
Journal:  J Hematol Oncol       Date:  2016-06-17       Impact factor: 17.388

8.  Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1.

Authors:  Chao Zhou; Fangrui Wu; Lianghao Lu; Liping Wei; Eric Pai; Yuan Yao; Yongcheng Song
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

Review 9.  Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases.

Authors:  Hideaki Niwa; Takashi Umehara
Journal:  Epigenetics       Date:  2017-02-10       Impact factor: 4.528

Review 10.  Epigenetic assays for chemical biology and drug discovery.

Authors:  Sheraz Gul
Journal:  Clin Epigenetics       Date:  2017-04-21       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.